Glecaprevir

Contraindicated

Glecaprevir Colchicine Colcrys Explained Increased colchicine exposure and an increased risk of colchicine toxicity Details

Major

Glecaprevir Relugolix Orgovyx Explained Increased relugolix exposure Details Glecaprevir Simvastatin Flolipid Explained Increased simvastatin exposure and increased risk of myopathy Details Glecaprevir Alpelisib Piqray Increased alpelisib exposure and an increased risk of alpelisib-related adverse effects and toxicity Details Glecaprevir Atogepant Qulipta Increased atogepant exposure Details Glecaprevir Atorvastatin Atorvaliq Increased atorvastatin exposure and an increased risk of myopathy and rhabdomyolysis Details Glecaprevir Capmatinib Tabrecta Increased P-gp substrate exposure and an increased risk of increased adverse reactions Details Glecaprevir Cyclosporine Injection Atopica Increased glecaprevir exposure and an increased cycloSPORINE exposure Details Glecaprevir Cyclosporine Ophthalmic Cequa Increased glecaprevir exposure and an increased cycloSPORINE exposure Details Glecaprevir Dabigatran Pradaxa® Increased dabigatran exposure and an increased risk of bleeding Details Glecaprevir Dabigatran Etexilate Increased dabigatran exposure and an increased risk of bleeding Details Glecaprevir Darolutamide Nubeqa Increased exposure of OATP1B1 or OATP1B3 substrates Details Glecaprevir Doxorubicin Adriamycin Increased DOXOrubicin exposure and an increased risk of DOXOrubicin-related adverse reactions Details Glecaprevir Finerenone Kerendia Increased finerenone exposure and an increased risk of finerenone-related adverse effects Details Glecaprevir Lefamulin Xenleta Increased lefamulin exposure and an increased risk of lefamulin-related adverse reactions Details Glecaprevir Lenacapavir Injection Sunlenca Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse reactions Details Glecaprevir Lenacapavir Oral Sunlenca Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse reactions Details Glecaprevir Leniolisib Joenja Increased OATP1B1/OATP1B3 substrate exposure Details Glecaprevir Loperamide Diamode An increased loperamide exposure and an increased risk of loperamide-related adverse reactions Details Glecaprevir Lovastatin Altocor® Increased lovastatin exposure and increased risk of myopathy Details Glecaprevir Methylergonovine Methergine Increased methylergonovine exposure Details Glecaprevir Morphine Injection Astramorph® PF Increased morphine exposure and an increased risk of morphine-related adverse effects (hypotension, respiratory depression, profou... Details Glecaprevir Nifedipine Adalat® Increased NIFEdipine exposure Details

Moderate

Glecaprevir Acarbose Prandase® Explained Altered glycemic control resulting in severe symptomatic hypoglycemia Details Glecaprevir Alogliptin Nesina Altered glycemic control resulting in severe symptomatic hypoglycemia Details Glecaprevir Canagliflozin Invokana Altered glycemic control resulting in severe symptomatic hypoglycemia Details Glecaprevir Dapagliflozin Farxiga Altered glycemic control resulting in severe symptomatic hypoglycemia Details Glecaprevir Digoxin Cardoxin® Increased digoxin exposure Details Glecaprevir Dofetilide Tikosyn Increased dofetilide exposure Details Glecaprevir Dulaglutide Injection Trulicity Altered glycemic control resulting in severe symptomatic hypoglycemia Details Glecaprevir Empagliflozin Glyxambi® (as a combination product containing Empagliflozin and Linagliptin) Altered glycemic control resulting in severe symptomatic hypoglycemia Details Glecaprevir Encorafenib Braftovi Increased OATP1B1 substrate exposure, increased OATP1B3 substrate exposure, increased risk of OATP1B1 substrate-related toxicities... Details Glecaprevir Ertugliflozin Steglatro Altered glycemic control resulting in severe symptomatic hypoglycemia Details Glecaprevir Exenatide Injection Bydureon Altered glycemic control resulting in severe symptomatic hypoglycemia Details Glecaprevir Fluvastatin Lescol Increased fluvastatin exposure and an increased risk of myopathy Details Glecaprevir Glimepiride Amaryl Altered glycemic control resulting in severe symptomatic hypoglycemia Details Glecaprevir Glipizide Glucotrol Altered glycemic control resulting in severe symptomatic hypoglycemia Details Glecaprevir Hydrocortisone Ala-Cort Increased hydrocortisone exposure and an increased risk of hydrocortisone-related adverse reactions Details Glecaprevir Hydrocortisone Injection A-Hydrocort® Increased hydrocortisone exposure and an increased risk of hydrocortisone-related adverse reactions Details Glecaprevir Insulin Degludec (Rdna Origin) Injection Ryzodeg® (as a combination product containing Insulin Degludec and Insulin Aspart) Altered glycemic control resulting in severe symptomatic hypoglycemia Details